BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein-Reference-Cited by-同舟云学术

BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein

Published:2013-12-02 Issue:3 Volume:28 Page:1221-1236
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Buffa Pietro¹,Romano Chiara²,Pandini Alessandro¹,Massimino Michele²,Tirrò Elena²,Di Raimondo Francesco²,Manzella Livia²,Fraternali Franca¹,Vigneri Paolo G.²³

Affiliation:

1. Randall Division of Cell and Molecular BiophysicsKing's College LondonLondonUK

2. Department of Clinical and Molecular BiomedicineUniversity of CataniaCataniaItaly

3. Department of Hematology, Oncology, and Molecular MedicineIstituto Superiore di SanitàRomeItaly

Funder

Biotechnology and Biological Sciences Research Council

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.13-236992

Reference67 articles.

1. Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

2. Chronic myeloid leukaemia as a model of disease evolution in human cancer

3. International Randomized Study of Interferon vs STI571 (IRIS) 8‐year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML‐CP) treated with imatinib;Deininger M.;Blood (ASH Annu. Meet. Abstr.),2009

4. New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance

5. Translation of the Philadelphia chromosome into therapy for CML

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability;OncoTargets and Therapy;2023-10

2. Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells;Frontiers in Endocrinology;2023-06-09

3. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells;Journal of Clinical Medicine;2021-11-29

4. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts;Frontiers in Pharmacology;2021-06-30

5. Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors;Journal of Biomolecular Structure and Dynamics;2021-06-14